Related Experiment Video
Updated: Aug 15, 2026

Real-time Imaging of Leukotriene B4 Mediated Cell Migration and BLT1 Interactions with β-arrestin
Published on: December 23, 2010
Pharmacological cross-reactivity between 5-lipoxygenase-activating protein, 5-lipoxygenase, and leukotriene C4
N Gupta1, D W Nicholson, A W Ford-Hutchinson
1Department of Pharmacology and Therapeutics, McGill University, Montréal, QC, Canada. Namrata_Gupta@Merck.com
Abstract:
Leukotriene (LT) C4 synthase, an integral membrane protein, catalyzes the first committed step in the biosynthesis of the peptidyl leukotrienes, which have been implicated in various inflammatory disorders, including human bronchial asthma. To identify possible inhibitors of LTC4 synthase, synthetic compounds known to inhibit other proteins in the leukotriene biosynthetic pathway (5-lipoxygenase-activating protein, FLAP, and 5-lipoxygenase, 5-LO) or to antagonize leukotriene receptors (cys LT1) were tested for activity against LTC4 synthase. These assays were performed on enriched fractions of human LTC4 synthase purified from the human monocytic cell line THP-1. LTA4 and glutathione were used as substrates, and LTC4 product formation was monitored by reverse-phase high pressure liquid chromatography. Representative compounds from distinct structural classes were tested over a concentration range of 40 nM to 100 microM. The most potent inhibitor was found to be a previously established nanomolar 5-lipoxygenase inhibitor, 2-[2-[1-(4-chlorobenzyl)-4-methyl-6-[(5-phenylpyridin-2-yl)- methoxy]-4,5-dihydro-1H-thiopyrano[2,3,4-c,d]indol-2-yl]ethoxy]but anoic acid (L-699.333) of the phenylpyridine structural class of compounds. L-699.333 inhibited LTC4 synthase activity in vitro with an IC50 value of 3.9 microM and a Ki value of 0.25 microM, making it the most potent synthetic inhibitor known of this enzyme. Structure-activity analyses of other phenylpyridines indicated that the inhibition imparted by L-699.333 was retained following the replacement of the carboxylic acid group with other equivalents. Structurally diverse FLAP inhibitors tested against LTC4 synthase were all micromolar inhibitors of the enzyme over a 10-fold range, with MK-886 at 11 microM. These results implicate that compounds that bind competitively to arachidonic acid binding sites on FLAP and 5-LO recognize motifs that are also weakly conserved on the binding site of LTC4 synthase.
Related Concept Videos
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Adrenergic Agonists: Direct-Acting Agents
These agents can be classified...
Antiasthma Drugs: β2-Adrenoceptor Agonists
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

